Inherited diseases of lipoprotein metabolism may give rise to marked hypocholesterolemia with low or absent levels of LDL, depending on the gene involved and mode of inheritance of the condition, together with the severity of the mutation or mutations present. In this review, we discuss the recent developments in the genetics of LDL deficiency.
INTRODUCTION
Inherited diseases of lipoprotein metabolism may give rise to marked hypocholesterolemia with low or absent levels of LDL, depending on the gene involved and mode of inheritance of the condition, together with the severity of the mutation or mutations present. The most extreme form of these disorders is abetalipoproteinemia, characterized by the absence of apolipoprotein (apo) B-containing lipoproteins in plasma [1, 2] . Abetalipoproteinemia is caused by mutations in the microsomal triglyceride transfer protein gene (MTTP), presents in early childhood with fat malabsorption, steatorrhea and failure to thrive, and may include progressive neurological and ophthalmological abnormalities as the patient ages.
Low plasma concentrations (usually <50% of normal levels for age and sex) of LDL-cholesterol and apoB are observed in familial hypobetalipoproteinemia, a codominant disorder of lipoprotein metabolism caused by the inheritance of a mutation in APOB, usually giving rise to a truncated apoB protein [3] . Patients are generally asymptomatic, but may be at increased risk of fatty liver disease. Inheritance of two such mutations in APOB is known as homozygous familial hypobetalipoproteinemia and is clinically indistinguishable from abetalipoproteinemia.
In recent years, variants in the proprotein convertase subtilisin kexin 9 gene (PCSK9) have been shown to be associated with hypobetalipoproteinemia, although these have not been associated with any clinical symptoms. These loss-offunction mutations in PCSK9 result in reduced concentrations of LDL-cholesterol in a gene dosedependent manner, leading to a lifetime low risk of cardiovascular disease [4] .
A major recent finding has been the association between mutations in ANGPTL3 and recessive familial combined hypolipidemia, which is characterized by a reduction in all plasma lipids, including HDL-cholesterol. This review summarizes the recent advances in the field of genetic causes of LDL-deficiency, focusing on ANGPTL3.
ANGPTL3: A MODULATOR OF LIPOPROTEIN LIPASE ACTIVITY AND CAUSE OF HYPOLIPIDEMIA IN MICE
In 2002, it was reported that one strain of the KK obese mouse displayed abnormally low plasma lipid levels, inherited in a recessive manner. Mapping of the hypolipidemia trait to chromosome 4 and positional cloning identified a locus encoding a unique angiopoietin-like lipoprotein modulator, Angptl3, for which there is a highly conserved counterpart in humans [5] . As in mice, the majority of expression of ANGPTL3 in humans occurs in the liver [6] . ANGPTL3, along with ANGPTL4, modulates lipolysis via the post-transcriptional inhibition of lipoprotein lipase (LPL) [7, 8] ; mice lacking Angptl3 expression have increased LPL activity and reduced plasma triglyceride concentrations [5] . In addition, Angptl3-deficient mice show low plasma HDL-cholesterol and HDL-phospholipid; in-vitro studies suggest that ANGPTL3 inhibits the phospholipase activity of endothelial lipase [9] .
RARE VARIANTS IN ANGPTL3 ARE ASSOCIATED WITH HYPOTRIGLYCERIDEMIA IN HUMANS
In humans, ANGPTL3 consists of seven exons, encoding a 460 amino acid product. Romeo et al. [6] used a reverse genetic strategy to determine whether four members of the angiopoietinlike proteins (ANGPTL3, ANGPTL4, ANGPTL5 and ANGPTL6) played important roles in triglyceride metabolism in humans. Resequencing of the coding regions of these genes in the multiethnic Dallas Heart Study population (over 3500 patients) identified multiple rare nonsynonymous sequence variants associated with low plasma triglyceride concentrations. Overall, 1% of the study population, and 4% of those in the lowest quartile of triglycerides, carried a loss-of-function variant in ANGPTL3, ANGPTL4 or ANGPTL5. This included 35 sequence variants in ANGPTL3, with 14 in the lower quartile for plasma triglycerides compared with five in the upper quartile. Although some of the variants were nonsense, frameshift or splicing mutations, others were missense mutations of unknown effect. In-vitro expression studies of the mutant proteins in HEK293A cells showed that five of nine missense variants from the lowest triglyceride quartile group abolished secretion of ANGPTL3 from cells compared with none of the five missense variants from the highest triglyceride quartile group. The variants from the lowest quartile of triglyceride group also failed to suppress LPL activity in vitro. In addition, the ANGPTL3 M259T single nucleotide polymorphism (SNP) was present in 5% of African-Americans and was significantly associated with plasma triglycerides, with TT homozygotes showing plasma triglyceride levels $20% lower than those with the wild-type genotype MM.
While deletion of Angptl3 in mice is associated with a 50% reduction in plasma HDL-cholesterol levels [9] , the Dallas Heart Study cohort did not show an association of ANGPTL3 loss-of-function variants with HDL-cholesterol.
COMBINED HYPOLIPIDEMIA IS CAUSED BY MUTATIONS IN ANGPTL3
In a landmark publication in 2010, Musunuru et al. used exome sequencing to identify mutations in ANGPTL3 as the cause of hypobetalipoproteinemia in two siblings with extremely low plasma levels of LDL-cholesterol, HDL-cholesterol and triglyceride [10,11 && ]. The individuals were from a 38-member, three-generation family, which included four people with combined hypolipidemia and several with hypobetalipoproteinemia that was not linked to the APOB gene. Exome sequencing analysis showed that ANGPTL3 was the only gene that had novel variants in both alleles in both siblings. Both mutations were nonsense mutations, S17X and E129X, occurring in the first exon of ANGPTL3. Heterozygotes for either mutation had intermediate levels of LDL-cholesterol and triglycerides, consistent with a codominant mode of inheritance for these phenotypes. However, only the compound heterozygotes showed a marked reduction
KEY POINTS
Loss-of-function mutations in ANGPTL3 are associated with a recessive familial combined hypolipidemia characterized by a reduction in all plasma lipids, including HDL-cholesterol.
ANGPTL3 is absent in plasma of the patients with homozygous or compound heterozygous ANGPTL3 mutations.
The prevalence of ANGPTL3 mutations giving rise to a combined hypolipidemia phenotype in patients with severe primary hypobetalipoproteinemia is about 10%.
in HDL-cholesterol, indicating that this segregates as a recessive trait. This discrepancy suggests there are distinct mechanisms of action of ANGPTL3 on different lipoprotein classes.
FURTHER CHARACTERIZATION OF ANGPTL3 MUTATIONS ASSOCIATED WITH FAMILIAL COMBINED HYPOLIPIDEMIA
Pisciotta et al. [12 & ] characterized ANGPTL3 mutations in three families with combined hypolipidemia. The probands, aged 59, 65 and 85 years, each had a total cholesterol concentration below 2 mmol/l (80 mg/dl), with LDL-cholesterol $1 mmol/l (40 mg/dl), triglyceride $0.5 mmol/l (45 mg/dl) and HDL-cholesterol ranging from 0.26 to 0.70 mmol/l (10-27 mg/dl). DNA sequencing showed that they did not carry a mutation in the APOB, MTTP, PCSK9, APOA1, LCAT or ABCA1 genes. One proband was homozygous for an ANGPTL3 splice donor mutation, c.1198þ1G>T, which caused partial retention of intron 6 and introduction of a premature stop codon into the reading frame (p.G400VfsÃ5). Screening of 200 healthy individuals identified one heterozygous carrier with a normal lipid profile. The other two probands were compound heterozygotes for the same two deletions in exon 1 of ANGPTL3: c.55delA and c.439_442del, frameshift mutations leading to production of truncated proteins (p.I19LfsÃ22 and p.N147X, respectively). c.1198þ1G>T and c.439_442del mutations in heterozygous patients were previously described by Romeo et al. showed that the mean LDL-cholesterol in heterozygotes was below the 25th percentile of population distribution, so unlike carriers of APOB truncating mutations, would not be easily discernible in population screening for low LDL-cholesterol.
ANGPTL3 was absent in plasma of the patients with homozygous or compound heterozygous mutations, with heterozygotes showing reduced concentrations of circulating ANGPTL3 compared with the general population [12 & ]. Although their sera had a reduced capacity in vitro to promote cellular cholesterol efflux through the ABCA1, ABCG1 and SR-BI pathways, the ANGPTL3 À/À patients did not show any clinical evidence of accelerated atherosclerosis. The ability to promote cholesterol efflux was directly correlated with plasma HDL-cholesterol concentration. However, with the small number of patients, more studies are needed to firmly establish whether or not the lifelong exposure to low levels of LDL-cholesterol counterbalances the proatherogenic effects of low HDL-cholesterol.
In four unrelated Spanish families meeting the criteria for familial hypobetalipoproteinemia (apoB and LDL-cholesterol <5th percentile for age and sex), but without APOB mutations, two probands were found to be homozygotes for a 5 bp deletion in ANGPTL3, p.N121LÃ2 [13] . These individuals featured combined hypolipidemia including low triglyceride and HDL-cholesterol concentrations.
PREVALENCE OF ANGPTL3 MUTATIONS IN COMBINED HYPOLIPIDEMIA
Noto et al. [14 && ] determined that the prevalence of ANGPTL3 mutations giving rise to a combined hypolipidemia phenotype in patients with severe primary hypobetalipoproteinemia is about 10%. In two cohorts comprising 913 Italian and American patients with total cholesterol less than fifth percentile of the general population, they chose total cholesterol and HDL-cholesterol cut-offs of second percentile and the second decile based on data from a previously reported familial combined hypolipidemia kindred [11 && ]. This identified 78 patients with combined hypolipidemia. DNA sequencing identified ANGPTL3 gene mutations in eight patients and no PCSK9, MTTP or APOB mutations. Four patients were homozygous or compound heterozygous for ANGPTL3 mutations, and four were simple heterozygotes.
Overall, in this population study, APOB mutations are found in 7-8% of patients with total cholesterol less than second percentile [14 && ]. This suggests that in patients with total cholesterol less than second percentile, those with HDL-cholesterol less than second decile may be carrying ANGPTL3 mutations, whereas those with higher HDL-cholesterol may be carrying APOB mutations. Ultrasonography of three ANGPTL3 mutation carriers detected severe fatty liver in one patient, suggesting that this complication may not be limited to familial hypobetalipoproteinemia due to APOB mutations.
CLINICAL AND BIOCHEMICAL CHARACTERIZATION OF FAMILIAL COMBINED HYPOLIPIDEMIA CAUSED BY ANGPTL3 S17X
In 1991, Fazio et al.
[15] identified a threegeneration Italian family in the small Italian town of Campodimele with a dominant form of hypobetalipoproteinemia that was not due to a mutation in APOB. Recently, Minicocci et al. [16 && ] identified the ANGPTL3 S17X mutation in the proband of this family and also in the probands of an additional eight local families. Two of the probands were homozygous for the mutation whereas seven were heterozygotes. Family screening identified 20 further patients with ANGPTL3 S17X, including four homozygotes. Compared with noncarrier family members, those patients heterozygous for ANGPTL3 S17X had reduced HDL-cholesterol and triglyceride concentrations.
A voluntary screening program in which $60% of the town residents participated identified 32 other carriers of the ANGPTL3 mutation out of the 352 patients screened. Although 46 individuals had LDL-cholesterol less than fifth percentile for age and sex, only six carried S17X (four heterozygotes and two homozygotes). The remaining population were then screened, identifying a further 26 S17X heterozygotes. The prevalence of ANGPTL3 variants in the population was estimated to be 9.4%.
Overall, homozygosity for ANGPTL3 S17X reduced LDL-cholesterol by 48%, triglyceride by 62%, HDL-cholesterol by 46%, apoB by 44% and apoA-I by 48%. Of interest, heterozygotes only showed a significant reduction in total cholesterol and HDL-cholesterol [16 && ], in contrast with earlier findings suggesting that heterozygotes had lower LDL-cholesterol and triglyceride concentrations [11 && ]. This may relate to the specific mutation, a partial influence on plasma lipids, or other environmental or genetic differences between the studied individuals.
The prevalence of elevated liver enzymes was not different between ANGPTL3 S17X carriers and noncarriers, suggesting that familial combined hypolipidemia is not associated with liver abnormalities. Of interest, blood glucose levels were significantly lower in homozygotes than noncarriers. Romeo et al. [6] reported a higher prevalence of ANGPTL3 nonsynonymous variant carriers in those patients with the lowest quartile of blood glucose. The mechanism by which ANGPTL3 affects glucose levels is uncertain, but may relate to the reduction in lipolysis and free fatty acid availability, which may improve tissue insulin sensitivity [16 && ]. Plasma noncholesterol sterols and ratios were determined in carriers and noncarriers of ANGPTL3 mutant alleles. The indices of cholesterol absorption, cholesterol synthesis and bile acid metabolism were not different between groups, except for a higher mean lanosterol to total cholesterol ratio in homozygotes. However, the other marker of cholesterol synthesis, lathosterol to total cholesterol ratio, was not different. These data suggest that ANGPTL3 mutations do not cause significant alterations of whole-body cholesterol metabolism.
CONCLUSION
ANGPTL3, a protein produced in the liver and found in the circulation, inhibits the activity of LPL and endothelial lipase. Angptl3 knockout mice have marked recessive hypolipidemia. The identification of loss-of-function ANGPTL3 mutations as a cause of familial combined hypolipidemia suggests a new mechanism for the regulation of LDL metabolism in humans, thereby making ANGPTL3 an attractive protein to target for therapeutics.
